The Safety and Regulation Concerns Surrounding Peptides in Beauty and Wellness

The intersection of beauty and wellness has created a burgeoning industry worth $6.8 trillion. Yet, one highly-valued component—the peptide—raises safety and efficacy concerns. Experts at Northeastern University caution that peptide usage is outpacing safety research. This comes as the U.S. Food and Drug Administration (FDA) convenes to decide the future of peptide regulation, an issue championed by Robert F. Kennedy Jr., Secretary of the Department of Health and Human Services, due to his significant public health influence.

Pharmaceutical experts are scrutinizing whether peptides—tiny protein fragments promising to erase wrinkles or aid weight loss by binding with cell receptors—are ready for mass adoption. Some argue that regulators and patients are being asked to trust products without adequate evidence.

Peptides and the Rise of Wellness Trends

Buzzwords like “biohacking” and “longevity” now dominate personal care discourse, with peptides leading the trend over other innovations like NAD infusions and DNA-coded skincare. U.S. searches for peptides reached 10.1 million monthly in January, a fivefold increase since 2020. GLP-1 drugs like Ozempic and Mounjaro are prominent examples, used by 1 in 8 Americans. Even teenagers show interest, ready to go to greater lengths for beauty.

The situation could escalate if the FDA eases peptide drug restrictions, which FDA scientists warn remain underexplored. The Pharmacy Compounding Advisory Committee is reviewing expanding access to previously banned peptides, allowing specialized pharmacies to craft custom medications for individuals.

Emily G. Hilliard from HHS highlighted the committee’s role in evaluating risks and benefits, saying, “The committee’s recommendations will inform FDA’s decision-making.” After public input on a proposed rule, final decisions will consider multiple factors.

Experts’ Perspectives on Peptide Safety

In February, RFK Jr. suggested a major regulatory pivot, proposing the removal of 14 out of 19 banned peptides from the FDA’s restricted list—a significant regulatory shift.

Valerie Aparovich, a certified cosmetologist and biochemist, is optimistic about peptides, noting that topical varieties like Matrixyl support collagen and possess “high safety profiles.” However, she warns that much of the research is industry-originated.

Despite optimism, rare cases like two women falling ill at a Las Vegas festival in 2025 highlight potential dangers. Karthik Achari, a clinician who founded PepMD, stressed the gap between authorization and qualification to prescribe peptides, citing a lack of rigorous data. Achari argued for a regulated path as safer than unregulated markets.

Dr. Neil Panchal of Longevitix agrees that regulated pathways are safer, warning that lack of access sends consumers to gray markets with unverified products.

Mansoor Amiji, a professor at Northeastern University, underscores the absence of preclinical and clinical safety studies outside FDA-approved peptides, criticizing anecdotal claims of benefits. He warns of potential systemic absorption risks from topical use.

Steve Kates, a colleague, notes the lack of necessary manufacturing validation and efficacy studies for widespread approval. He argues these protocols remain unmet due to the complex nature of peptide manufacturing.

These insights highlight the ongoing debate over peptides’ readiness for mainstream use, with safety and efficacy at the forefront.